CA Patent

CA3111317C — Method of synthesizing thyroid hormone analogs and polymorphs thereof

Assigned to F Hoffmann La Roche AG · Expires 2023-08-29 · 3y expired

What this patent protects

Abstract THE DISCLOSURE DESCRIBES A MORPHIC FORM OF 2-(3,5-DICHLOR0-445-ISOPROPYL- 6-0X0- 1,6-DIHYDROPYRIDAZIN- 3 -YL)OXYPHENYL)-3 ,5 -DI OX0-2,3 ,4,5 - TETRAHYDRO- 1,2,4- TRIAZINE-6-CARBONITRILE ("COMPOUND A"), WHEREIN THE MORPHIC FORM IS A HYDRATE. ALSO DESCRIBED IS A P…

USPTO Abstract

Abstract THE DISCLOSURE DESCRIBES A MORPHIC FORM OF 2-(3,5-DICHLOR0-445-ISOPROPYL- 6-0X0- 1,6-DIHYDROPYRIDAZIN- 3 -YL)OXYPHENYL)-3 ,5 -DI OX0-2,3 ,4,5 - TETRAHYDRO- 1,2,4- TRIAZINE-6-CARBONITRILE ("COMPOUND A"), WHEREIN THE MORPHIC FORM IS A HYDRATE. ALSO DESCRIBED IS A PHARMACEUTICAL COMPOSITION COMPRISING THE MORPHIC FORM AND A PHARMACEUTICALLY ACCEPTABLE CARRIER. Date Recue/Date Received 2021-03-05

Drugs covered by this patent

Patent Metadata

Patent number
CA3111317C
Jurisdiction
CA
Classification
—
Expires
2023-08-29
Drug substance claim
No
Drug product claim
No
Assignee
F Hoffmann La Roche AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.